Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 281 to 290 of 1514 total matches.
Valacyclovir
The Medical Letter on Drugs and Therapeutics • Jan 05, 1996 (Issue 965)
of
The Medical Letter, Vol. 38 (Issue 965) January 5, 1996, pp. 3-4
Copyright The Medical Letter
UNAUTHORIZED ...
Valacyclovir (Valtrex - Glaxo Wellcome), an L- valyl ester of acyclovir (Zovirax), has been approved by the US Food and Drug Administration (FDA) for oral treatment of herpes zoster (shingles) in immunocompetent adults. Famciclovir (Famvir - Medical Letter, 36:97, 1994) is also available for this indication.
New Uses of Thalidomide
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996 (Issue 968)
, Nephron, 67:270,
The Medical Letter, Vol. 38 (Issue 968) February 16, 1996, pp. 15-16
Copyright ...
Thalidomide is now available as an investigational drug in the USA. A synthetic derivative of glutamic acid, it was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity (PF DArcy and JP Griffin, Adverse Drug React Toxicol Rev, 13:65, 1994). The drug has since been found effective for several different indications.
Methotrexate and Misoprostol for Abortion
The Medical Letter on Drugs and Therapeutics • Apr 26, 1996 (Issue 973)
, Jan 15, 1996).
The Medical Letter, Vol. 38 (Issue 973) April 26, 1996, pp. 39-40
Copyright ...
Recent articles in the press have suggested that in early pregnancy, an intramuscular (IM) injection of methotrexate (Folex, and others), a folic acid antagonist, and oral or vaginal administration of misoprostol (Cytotec), a prostaglandin, offers a medical alternative to a surgically induced abortion. Methotrexate is approved by the US Food and Drug Administration for use in rheumatoid arthritis, psoriasis and various types of cancer, including choriocarcinoma, and has also been used to terminate ectopic pregnancies. Misoprostol is approved for prevention of gastric ulcers induced by...
Clarithromycin and Omeprazole for Helicobacter Pylori
The Medical Letter on Drugs and Therapeutics • Jun 07, 1996 (Issue 976)
The Medical Letter, Vol. 38 (Issue 976) June 7, 1996, pp. 51-52
Copyright The Medical Letter
UNAUTHORIZED ...
The US Food and Drug Administration (FDA) recently approved the marketing of clarithromycin (Biaxin - Abbott), a macrolide antibiotic, and omeprazole (Prilosec - Astra Merck), a proton pump inhibitor, for concurrent use in treatment of duodenal ulcers associated with Helicobacter pylori.
Anastrozole for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jul 05, 1996 (Issue 978)
.
The Medical Letter, Vol. 38 (Issue 978) July 5, 1996, pp. 61-62
Copyright The Medical Letter
UNAUTHORIZED ...
Anastrozole (Arimidex - Zeneca), a selective nonsteroidal aromatase inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen (Nolvadex, and others).
Alteplase for Thrombolysis in Acute Ischemic Stroke
The Medical Letter on Drugs and Therapeutics • Nov 08, 1996 (Issue 987)
Letter, Vol. 38 (Issue 987) November 8, 1996, pp. 99-100
Copyright The Medical Letter
UNAUTHORIZED ...
Alteplase, a recombinant tissue plasminogen activator (TPA; Activase - Genentech), has been approved by the US Food and Drug Administration (FDA) for intravenous (IV) treatment of acute ischemic stroke. Several thrombolytic agents, including alteplase, were previously approved for use in acute myocardial infarction and acute massive pulmonary embolism (Medical Letter, 29:107, 1987; 32:15, 1990).
Sodium Phenylbutyrate for Urea Cycle Enzyme Deficiencies
The Medical Letter on Drugs and Therapeutics • Nov 22, 1996 (Issue 988)
Letter, Vol. 38 (Issue 988) November 22, 1996, pp. 105-106
Copyright The Medical Letter
UNAUTHORIZED ...
Sodium phenylbutyrate, an "orphan drug,"has recently been marketed for the treatment of patients with urea cycle disorders caused by a deficiency in one of the following hepatic enzymes: carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Urea cycle disorders are rare; they occur in one of every 10,000 births.
Clonidine for Treatment of Attention-Deficit/Hyperactivity Disorder
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996 (Issue 989)
improvement
The Medical Letter, Vol. 38 (Issue 989) December 6, 1996, p. 109-110
Copyright The Medical ...
Clonidine, an Alpha2-selective adrenergic agonist marketed in the USA only for treatment of hypertension, has also been used in recent years to treat children with attention-deficit/hyperactivity disorder (ADHD).
Reteplase (Retavase)
The Medical Letter on Drugs and Therapeutics • Feb 28, 1997 (Issue 995)
IV over 60 minutes) in 6,010 patients enrolled within 12 hours
The Medical Letter, Vol. 39 (Issue ...
Reteplase (Retavase - Boehringer Mannheim), a recombinant protein derivative of human tissue plasminogen activator (t-PA), has been marketed in the USA for thrombolysis in patients with acute myocardial infarction.
Adapalene for Acne
The Medical Letter on Drugs and Therapeutics • Feb 28, 1997 (Issue 995)
Letter, Vol. 39 (Issue 995) February 28, 1997, pp. 19-20
Copyright The Medical Letter
UNAUTHORIZED ...
Adapalene (Differin - Galderma), a synthetic retinoid analog, has been marketed in the USA in a 0.1% gel formulation for topical treatment of acne vulgaris.